TY - JOUR
T1 - Fungaemia in haematological malignancies
T2 - SEIFEM-2015 survey
AU - the SEIFEM Group (Sorveglianza Epidemiologica Infezioni nelle Emopatie)
AU - Criscuolo, Marianna
AU - Marchesi, Francesco
AU - Candoni, Anna
AU - Cattaneo, Chiara
AU - Nosari, Annamaria
AU - Veggia, Barbara
AU - Verga, Luisa
AU - Fracchiolla, Nicola
AU - Vianelli, Nicola
AU - Del Principe, Maria Ilaria
AU - Picardi, Marco
AU - Tumbarello, Mario
AU - Aversa, Franco
AU - Busca, Alessandro
AU - Pagano, Livio
AU - Dragonetti, Giulia
AU - Ballanti, Stelvio
AU - Delia, Mario
AU - Nadali, Gianpaolo
AU - Sciumè, M.
AU - Castagnola, C.
AU - Ferrari, A.
AU - Mancini, V.
AU - Decembrino, N.
AU - Spolzino, A.
AU - Iovino, L.
AU - Martino, B.
AU - Vacca, A.
AU - Calore, E.
AU - Fanci, R.
AU - Lessi, F.
AU - Vallero, S.
AU - Zama, D.
AU - Cesaro, S.
AU - De Paolis, M. R.
AU - Facchini, L.
AU - Muggeo, P.
AU - Offidani, M.
AU - Perruccio, K.
AU - Russo, D.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Background: Fungal infections are still a relevant challenge for clinicians involved in the cure of patients with cancer. We retrospectively reviewed charts of hospitalized patients with haematological malignancies (HMs), in which a documented fungaemia was diagnosed between January 2011 and December 2015 at 28 adult and 6 paediatric Italian Hematology Departments. Methods: During the study period, we recorded 215 fungal bloodstream infections (BSI). Microbiological analyses documented that BSI was due to moulds in 17 patients (8%) and yeasts in 198 patients (92%), being Candida spp identified in 174 patients (81%). Results: Mortality rates were 70% and 39% for mould and yeast infections, respectively. Infection was the main cause of death in 53% of the mould and 18% of the yeast groups. At the multivariate analysis, ECOG ≥ 2 and septic shock were significantly associated with increased mortality, and removal of central venous catheter (CVC) survival was found to be protective. When considering patients with candidemia only, ECOG ≥ 2 and removal of CVC were statistically associated with overall mortality. Conclusions: Although candidemia represents a group of BSI with a good prognosis, its risk factors largely overlap with those identified for all fungaemias, even though the candidemia-related mortality is lower when compared to other fungal BSI. Management of fungal BSI is still a complex issue, in which both patients and disease characteristics should be focused to address a personalized approach.
AB - Background: Fungal infections are still a relevant challenge for clinicians involved in the cure of patients with cancer. We retrospectively reviewed charts of hospitalized patients with haematological malignancies (HMs), in which a documented fungaemia was diagnosed between January 2011 and December 2015 at 28 adult and 6 paediatric Italian Hematology Departments. Methods: During the study period, we recorded 215 fungal bloodstream infections (BSI). Microbiological analyses documented that BSI was due to moulds in 17 patients (8%) and yeasts in 198 patients (92%), being Candida spp identified in 174 patients (81%). Results: Mortality rates were 70% and 39% for mould and yeast infections, respectively. Infection was the main cause of death in 53% of the mould and 18% of the yeast groups. At the multivariate analysis, ECOG ≥ 2 and septic shock were significantly associated with increased mortality, and removal of central venous catheter (CVC) survival was found to be protective. When considering patients with candidemia only, ECOG ≥ 2 and removal of CVC were statistically associated with overall mortality. Conclusions: Although candidemia represents a group of BSI with a good prognosis, its risk factors largely overlap with those identified for all fungaemias, even though the candidemia-related mortality is lower when compared to other fungal BSI. Management of fungal BSI is still a complex issue, in which both patients and disease characteristics should be focused to address a personalized approach.
KW - acute leukaemias
KW - candidemia
KW - fungaemia
UR - http://www.scopus.com/inward/record.url?scp=85062717222&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062717222&partnerID=8YFLogxK
U2 - 10.1111/eci.13083
DO - 10.1111/eci.13083
M3 - Article
AN - SCOPUS:85062717222
SN - 0014-2972
VL - 49
JO - European Journal of Clinical Investigation
JF - European Journal of Clinical Investigation
IS - 5
M1 - e13083
ER -